Health Care Reform and Possible Effects on Innovative Therapies: Cancer as a Case Study : Hearing Before the Subcommittee on Technology, Environment, and Aviation of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, Second Session, February 2, 1994, Volume 4

Front Cover

From inside the book

Other editions - View all

Common terms and phrases

Popular passages

Page 76 - Never doubt that a small group of thoughtful committed citizens can change the world. Indeed it's the only thing that ever has.
Page 53 - Less Than the Sum of Its Parts: Reforms Needed in the Organization, Management, and Resources of the Food and Drug Administration's Center for Devices and Radiological Health.
Page 156 - In fact, a recent congressional Office of Technology Assessment report concludes that " the success of the health-care oriented biotechnology industry in raising external capital proves that companies raise substantial R&D capital in external capital markets when future prospects look promising...
Page 129 - Kaposi's sarcoma (KS) was examined with the use of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
Page 183 - S&P 500 Stock Market Index. These companies have lost almost 25 percent of their value relative to the overall market. These companies compete for capital in the financial markets. Lower market values mean that the cost of capital is going up and less capital is available. Ultimately, capital flows are reflected in research budgets as well as in prices. As I mentioned, I have been involved in several high tech ventures. Currently, "word on the street" is that capital for biotech start-ups has become...
Page 5 - I thank all of you for being here, and I look forward to hearing your testimony. Thank you, Mr. Chairman.
Page 68 - I would be pleased to answer any questions you might have. Thank you. [The prepared statement of Mr.
Page 3 - Thank you very much, Mr. Chairman. I first want to express my...
Page 17 - This survey did not cover the cost of developing a biotechnology drug, but analyses done by our industry find that the cost of developing a biotechnology drug may be similar. We know that Genzyme and Amgen, two of our member companies, raised $328 and $264 million, respectively, in equity before they brought their first products to market.
Page 183 - S 2 billion on a new Federal bureaucracy? Our deficits prove that we can't pay for the bureaucracy we already have. The irony of this foolishness as shown in Figure 8 is that Pharmaceuticals account for only 8 percent of total health expenditures. If all drugs were free, it would barely matter to .the overall cost of health, care in the. US Private capital is already noving away fron health care reeeereh.

Bibliographic information